BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $247 from $230 and keeps a Buy rating on the shares. Favorable Phase 3 topline data from the HERIZON-GEA-01 study in gastric cancer suggest Ziihera is an approvable drug in first-line GEA, a market the firm estimates could equate to greater than $600M in the U.S. and greater than $1.1B in global peak sales, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Jazz Pharmaceuticals price target raised to $225 from $185 at Jefferies
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Jazz Pharmaceuticals rises 20.6%